Cover Image
市場調查報告書

肺癌治療市場上已上市藥物及開發平台藥物候補分析

A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market

出版商 Frost & Sullivan 商品編碼 323658
出版日期 內容資訊 英文 74 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肺癌治療市場上已上市藥物及開發平台藥物候補分析 A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market
出版日期: 2015年01月28日 內容資訊: 英文 74 Pages
簡介

肺癌治療市場上,發現新的標靶治療藥,預計將取代傳統的治療方法。高成本效率的治療及標靶治療成為該市場的未滿足需求。

本報告提供肺癌治療的已上市藥物及開發平台藥物候補的相關調查、各種藥物類別、作用機制、臨床試驗的時間軸及結果、產品的銷售/核准時間表、流行病學、其他重要資料、各開發階段的競爭環境、關注的企業、產業趨勢分析等詳細內容彙整。

第1章 摘要整理

第2章 調查手法、調查範圍

第3章 市場概要

  • 市場概要:各種類
  • 最近的市場發展
  • 值得注意的企業
  • 主要的M&A、聯盟的評估
  • 改變市場流程的策略

第4章 流行病學

第5章 競爭情形

  • 競爭環境:已上市藥物及開發平台第三階段&已申請藥物
  • 競爭環境:開發平台第一階段及第二階段藥物
  • 到產品的銷售/核准為止的時間表
  • 專利到期的時間軸
  • 競爭環境:樞紐試驗

第6章 已上市產品

第7章 開發平台藥物分析

第8章 產品開發動態即時看板系統:最近核準的藥物、開發後期的開發平台藥物候補

  • 產品開發動態即時看板系統:TarcevaR (Erlotinib)-Roche Group
  • 產品開發動態即時看板系統:GilotrifR (Afatinib)-Boehringer Ingelheim
  • 產品開發動態即時看板系統:AvastinR (Bevacizumab)-Genentech Inc. (Roche Group)
  • 產品開發動態即時看板系統:AlimtaR (Pemetrexed)-Eli Lilly and Company
  • 產品開發動態即時看板系統:XALKORIR (Crizotinib)-Pfizer Inc.
  • 產品開發動態即時看板系統:AP26113-Ariad Pharmaceuticals, Inc.
  • 產品開發動態即時看板系統:Necitumumab-Eli Lilly and Company
  • 產品開發動態即時看板系統:Nivolumab-Bristol-Myers Squibb Company、小野藥品工業

第9章 總論

  • 結論
  • 免責聲明

第10章 附錄

第11章 關於FROST & SULLIVAN

目錄
Product Code: MAC3-01-00-00-00

Discovery of New Targeted Therapies Will Replace Conventional Therapies

This study assesses marketed and in-research products and combination regimens for the lung cancer therapeutics market. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented by their mechanism of action against cancer. Cost-effective treatments and targeted therapies are the key unmet needs of the market.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Executive Summary
  • 2. Executive Summary (continued)
  • 3. Executive Summary (continued)

2. METHODOLOGY AND SCOPE

  • 1. Methodology and Scope

3. MARKET OVERVIEW

  • 1. Market Overview-Segmentation
  • 2. Market Overview-Segmentation (continued)
  • 3. Market Overview-Segmentation (continued)
  • 4. Recent Market Developments
  • 5. Companies to Watch
  • 6. Key Merger, Acquisition, and Partnership Assessment
  • 7. Game-changing Strategies

4. EPIDEMIOLOGY

  • 1. Epidemiology
  • 2. Epidemiology (continued)
  • 3. Epidemiology (continued)

5. COMPETITIVE LANDSCAPE

  • 1. Competitive Landscape-Marketed and Pipeline Drugs in Pre-registration and Phase 3
  • 2. Competitive Landscape-Pipeline Drugs in Phase 1 and Phase 2
  • 3. Timeline of Product Launches/Approval
  • 4. Timeline of Patent Expiries
  • 5. Competitive Landscape-Pivotal Clinical Trials
  • 6. Competitive Landscape-Pivotal Clinical Trials (continued)

6. MARKETED PRODUCTS

  • 1. Marketed Products Synopsis
  • 2. Marketed Products Synopsis (continued)
  • 3. Marketed Products Synopsis (continued)
  • 4. Marketed Products Synopsis (continued)

7. PIPELINE DRUGS ANALYSIS

  • 1. Pipeline Synopsis
  • 2. Pipeline Synopsis (continued)
  • 3. Pipeline Synopsis (continued)
  • 4. Pipeline Synopsis (continued)
  • 5. Pipeline Synopsis (continued)
  • 6. Pipeline Synopsis (continued)
  • 7. Pipeline Synopsis (continued)
  • 8. Pipeline Synopsis (continued)
  • 9. Pipeline Synopsis (continued)
  • 10. Pipeline Synopsis (continued)
  • 11. Pipeline Synopsis (continued)
  • 12. Pipeline Synopsis (continued)
  • 13. Pipeline Synopsis (continued)
  • 14. Pipeline Synopsis (continued)
  • 15. Pipeline Synopsis (continued)
  • 16. Pipeline Synopsis (continued)
  • 17. Pipeline Synopsis (continued)

8. PRODUCT DASHBOARD OF RECENTLY APPROVED DRUGS AND LATE-STAGE PIPELINE DRUG CANDIDATES

  • 1. Product Dashboard: Tarceva® (Erlotinib)-Roche Group
  • 2. Product Dashboard: Gilotrif® (Afatinib)-Boehringer Ingelheim
  • 3. Product Dashboard: Avastin® (Bevacizumab)-Genentech Inc. (Roche Group)
  • 4. Product Dashboard: Alimta® (Pemetrexed)-Eli Lilly and Company
  • 5. Product Dashboard: XALKORI® (Crizotinib)-Pfizer Inc.
  • 6. Product Dashboard: AP26113-Ariad Pharmaceuticals, Inc.
  • 7. Product Dashboard: Necitumumab-Eli Lilly and Company
  • 8. Product Dashboard: Nivolumab-Bristol-Myers Squibb Company and Ono Pharmaceutical

9. CONCLUSIONS

  • 1. Conclusions
  • 2. Legal Disclaimer

10. APPENDIX

  • 1. About Lung Cancer
  • 2. About Lung Cancer (continued)

11. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top